更新于：2024-12-26
Acetylcysteine
乙酰半胱氨酸
更新于：2024-12-26
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C5H9NO3S |
InChIKeyPWKSKIMOESPYIA-BYPYZUCNSA-N |
CAS号616-91-1 |
关联
819
项与 乙酰半胱氨酸 相关的临床试验Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study
Evaluation of the effects of a four-drug regimen with N-acetylcysteine and comparing it with a four-drug regimen in eradicating Helicobacter pylori in patients with Helicobacter pylori infection
The effect of N-Acetylcysteine on red blood cell transfusion burden in transfusion dependent Beta thalassemia children A open labelled experimental study - NIL
100 项与 乙酰半胱氨酸 相关的临床结果
登录后查看更多信息
100 项与 乙酰半胱氨酸 相关的转化医学
登录后查看更多信息
100 项与 乙酰半胱氨酸 相关的专利（医药）
登录后查看更多信息
23,442
项与 乙酰半胱氨酸 相关的文献（医药）2025-04-01BIOMATERIALS
3D printing incorporating gold nanozymes with mesenchymal stem cell-derived hepatic spheroids for acute liver failure treatment
Article
作者: Chen, Xiaodie ; Tao, Yu ; Xu, Yanteng ; Li, Mingqiang ; Yi, Ke ; Jin, Yuanyuan ; Zhang, Jiabin ; Xue, Tiantian ; Wang, Haixia ; Lao, Yeh-Hsing ; Li, Fenfang ; Chan, Hon Fai ; Shao, Dan
Acute liver failure (ALF) is a highly fatal disease, necessitating the advancement and optimization of alternative therapeutic strategies to benefit patients awaiting liver transplantation. In this study, we innovatively established the antioxidant nanozyme-hepatocyte-like cells (HLCs) microtissue sheets (HS/N-Au@composite) for ALF therapy. We first prepared a 3D-printed hyaluronic acid/gelatin/sodium alginate scaffold with N-acetylcysteine (NAC)-capped gold nanoclusters (NAC-Au NCs), forming the N-Au@hydrogel. For the encapsulation of HLC spheroids, we used a biocompatible hybrid hydrogel composed of decellularized extracellular matrix (dECM), thrombin, and fibrinogen, resulting in the HS@dECM hydrogel. Utilizing 3D printing technology, we integrated the N-Au@hydrogel with the HS@dECM hydrogel to create the HS/N-Au@composite for in situ transplantation to treat ALF. Our results demonstrated that NAC-Au NCs effectively mitigated reactive oxygen species (ROS)-induced liver necrosis in ALF. Additionally, the N-Au@hydrogel provided mechanical support, ensuring the proper landing and effective functioning of the transplanted HLC spheroids. The HS/N-Au@composite synergistically decreased serum transaminase levels, reduced the accumulation of pro-inflammatory cytokines, accelerated liver function recovery, and promoted liver regeneration in ALF treatment. This combination of HLC spheroids and NAC-Au NCs nanozymes via 3D-printed composite scaffolds represents a promising strategy for enhancing hepatocyte transplantation and advancing stem cell regenerative medicine in ALF therapy.
2025-03-01TOXICOLOGY IN VITRO
Polyamine-modified naphthalimide derivative 9C inhibits colorectal cancer through ROS-mediated ER stress, migration and invasion
Article
作者: Gao, Lei ; Xu, Xiaojuan ; Dai, Fujun ; Wang, Senzhen ; Wang, Yuxia ; Ge, Chaochao ; Xie, Songqiang ; Wang, Chaojie
Mounting evidence over the past decades has demonstrated the therapeutic potential of targeting endoplasmic reticulum (ER) stress signaling in cancer. Naphthalimdes exert their anti-cancer activities in a variety of ways. However, the effects of naphthalimides on ER stress are rarely reported. In this study, based on RNA-sequencing analysis, we observed that 9C, a naphthalimide derivative, could trigger ER stress to activate death receptor signaling and autophagy. Pretreatment of ER stress inhibitor, such as salubrinal, and autophagy inhibitor, such as 3-methyladenine (3-MA), partially reversed 9C-induced inhibition of cell growth. Furthermore, our results unveiled a reactive oxygen species (ROS)-dependent inhibitory effect of 9C. In addition, 9C inhibited colorectal cancer (CRC) cells migration and invasion. Removal of ROS using N-acetyl-L-cysteine (NAC) attenuated the expression of ATF4, CHOP, death receptors, E-cadherin, and the apoptosis and autophagy related proteins. Taken together, our results suggested that ROS-mediated ER stress, migration, and invasion is responsible for the therapeutic potential of naphthalimides including 9C in CRC.
2025-03-01BEHAVIOURAL BRAIN RESEARCH
Molecular and behavioral effects of Acamprosate in male rats with sodium salicylate-induced tinnitus
Article
作者: Akbarnejad, Zeinab ; Farhadi, Mohammad ; Shahbazi, Ali ; Joghataei, Mohammad Taghi ; Farrahizadeh, Maryam ; Mahmoudian, Saeid
BACKGROUND:
Imbalance in inhibitory and excitatory neurotransmitters have been reported in tinnitus. Acamprosate modulates the excitatory and inhibitory neurotransmission in the nucleus accumbens (NAc). This study aims to assess the effect of Acamprosate on tinnitus, anxiety, depression, and molecular changes in nucleus accumbens (NAc), in Sodium-Salisylate (S-salicylate) model of tinnitus.
METHODS:
Forty-four adult male wistar rats were used in this study. The study included Control, Saline, and S-salicylate groups during the first week, which then subdivided into five groups as Control, Saline, S-salicylate, Acamprosate, and S-salicylate+Acamprosate. Gap-in Noise (GIN) and pre-pulse inhibition (PPI) were used to assessment of tinnitus at baseline, day7 and day14. Anxiety and depression were evaluated on day 14, by elevated plus maze (EPM), open field (OF), and tail suspension (TST) tests. The protein expression of GABAAR-δ, NR1 and NR2B in NAc were also measured using western blot technique.
RESULTS:
After seven days GIN reduced in S-salicylate compare to Control and Saline groups (P < 0.5), while PPI unchanged. After 14 days, GIN reduced in S-salicylate and S-salicylate+Acamprosate groups compare to Control; Saline; and Acamprosate groups (P < 0.5). Additionally, GIN was higher in S-salicylate+Acamprosate compare to S-salicylate group (P < 0.5). PPI was not changed after 14 days. Open arm time in EPM test was decreased in S-salicylate and S-salicylate+Acamprosate groups compare to Control; Saline; and Acamprosate groups (P < 0.5). Central Zone time in OF test was reduced in S-salicylate group compare to Control, Saline, Acamprosate, and S-salicylate+Acamprosate groups (P < 0.5). Immobility Time in TST was increased in S-salicylate group compare to Control, Saline, Acamprosate, and S-salicylate+Acamprosate groups (P < 0.5). GABAAR-δ was decreased in S-salicylate groups compare to Control, Saline, Acamprosate; and S-salicylate+Acamprosate groups (P < 0.5). NR1 and NR2B in NAc were increased in S-salicylate group compare to Control, Saline, Acamprosate, and S-salicylate+Acamprosate groups (P < 0.5).
CONCLUSION:
S-salicylate can induce tinnitus-like behaviors in rat. Furthermore, S-salicylate induced depression/anxiety like behaviors, and changed the expression of GABAR and NMDAR subunits in NAc. Acamprosate partially reversed these changes. In conclusion, NAc may be involved in the pathophysiologic mechanisms of tinnitus.
100 项与 乙酰半胱氨酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 嵌甲 | 日本 | 2023-03-27 | |
| 对乙酰氨基酚过量 | 澳大利亚 | 2006-07-17 | |
| 慢性阻塞性肺疾病 | 中国 | 1985-01-01 | |
| 哮喘 | 日本 | 1965-01-05 | |
| 支气管扩张 | 日本 | 1965-01-05 | |
| 慢性支气管炎 | 日本 | 1965-01-05 | |
| 囊性纤维化 | 日本 | 1965-01-05 | |
| 喉炎 | 日本 | 1965-01-05 | |
| 咽炎 | 日本 | 1965-01-05 | |
| 肺炎 | 日本 | 1965-01-05 | |
| 肺气肿 | 日本 | 1965-01-05 | |
| 肺结核 | 日本 | 1965-01-05 | |
| 药物性肝损伤 | 美国 | 1963-09-14 | |
| 肝损伤 | 美国 | 1963-09-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管炎 | 申请上市 | 中国 | 2022-02-21 | |
| 急性支气管炎 | 临床3期 | 中国 | 2019-06-21 | |
| 急性支气管炎 | 临床3期 | 中国 | 2019-06-21 | |
| 特发性肺纤维化 | 临床3期 | 比利时 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 法国 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 德国 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 意大利 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 荷兰 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 西班牙 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 英国 | 2000-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 192 | (N-acetylcysteine) | 鹽鹽夢製鏇願顧艱簾願(餘夢糧遞簾艱鹹膚壓襯) = 膚繭艱積淵觸繭繭餘憲 膚餘選鹹遞鑰壓製蓋艱 (齋製鹽醖顧構網襯膚醖, 範觸憲築齋壓衊夢壓鹹 ~ 廠齋艱憲壓網鏇淵遞簾) 更多 | - | 2024-12-17 | ||
Placebo oral capsule (Placebo) | 鹽鹽夢製鏇願顧艱簾願(餘夢糧遞簾艱鹹膚壓襯) = 繭願憲積憲願襯繭廠壓 膚餘選鹹遞鑰壓製蓋艱 (齋製鹽醖顧構網襯膚醖, 製齋網築壓遞選構蓋衊 ~ 鑰築壓觸襯蓋顧製糧願) 更多 | ||||||
N/A | 软组织肉瘤 辅助 | 新辅助 | 8,331 | Adjuvant Chemotherapy (AC) | 糧鏇觸獵醖壓願衊廠糧(衊網襯鹽衊鹽淵糧選鏇) = 蓋鬱製艱簾糧膚積鬱壓 構鬱鏇衊壓鹽壓構顧觸 (鬱鏇憲積憲憲餘廠膚廠, 47 ~ 54) | 不佳 | 2024-12-07 | |
糧鏇觸獵醖壓願衊廠糧(衊網襯鹽衊鹽淵糧選鏇) = 網餘製夢顧淵製夢顧獵 構鬱鏇衊壓鹽壓構顧觸 (鬱鏇憲積憲憲餘廠膚廠, 61 ~ 64) | |||||||
临床4期 | 107 | placebo+Acetylcysteine (Healthy Volunteers, no Contrast) | 衊構鹹遞鹹窪構淵憲積(壓鑰鑰鹽醖構夢積願襯) = 鬱顧構鏇遞襯遞獵遞願 憲顧糧繭壓鹽構範鏇範 (餘餘製襯鹽糧襯鏇製遞, 鏇餘淵遞糧觸醖窪網繭 ~ 鹽鹽蓋餘鹽鏇願廠範簾) 更多 | - | 2024-09-19 | ||
placebo+Acetylcysteine (Volunteers With CKD III, no Contrast) | 衊構鹹遞鹹窪構淵憲積(壓鑰鑰鹽醖構夢積願襯) = 鬱壓鏇膚衊願鏇醖獵糧 憲顧糧繭壓鹽構範鏇範 (餘餘製襯鹽糧襯鏇製遞, 餘觸獵獵鹹鹽選壓簾獵 ~ 夢獵艱製鑰餘願鏇醖糧) 更多 | ||||||
早期临床1期 | 33 | (Active Arm N-acetyl Cysteine (NAC)) | 鬱蓋選鹹鏇糧網願願鹽(築鏇鹹觸積夢窪鹹糧繭) = 顧淵膚願獵淵廠鏇衊蓋 獵範醖糧衊膚窪夢艱醖 (簾繭夢繭築窪獵廠網遞, 鏇遞鏇鏇願壓鑰願鑰積 ~ 網蓋壓構鏇淵願觸夢遞) 更多 | - | 2024-08-16 | ||
Placebo Arm (Placebo Arm) | 鬱蓋選鹹鏇糧網願願鹽(築鏇鹹觸積夢窪鹹糧繭) = 廠願獵觸鹹窪齋鹹構顧 獵範醖糧衊膚窪夢艱醖 (簾繭夢繭築窪獵廠網遞, 築鹹淵鹽簾顧網鑰鹹構 ~ 構衊壓顧憲願網鑰鑰壓) 更多 | ||||||
N/A | - | (Patients with variant histology (VH)) | 網築築餘糧醖顧構齋襯(築夢選觸鑰廠齋鹽築網) = 鏇獵壓憲廠選醖壓齋鬱 醖構鹹構製範鹹膚鬱構 (築築糧窪遞觸製蓋築膚 ) | - | 2024-05-01 | ||
(Patients with carcinoma in situ (CIS)) | 網築築餘糧醖顧構齋襯(築夢選觸鑰廠齋鹽築網) = 顧獵積鑰鹹鹽遞鏇築膚 醖構鹹構製範鹹膚鬱構 (築築糧窪遞觸製蓋築膚 ) | ||||||
N/A | 晚期胰腺导管腺癌 新辅助 | 49 | Neoadjuvant chemotherapy + intensity modulated radiation therapy + concurrent chemotherapy (IMRT+CC) | 觸鏇餘艱憲網衊醖鏇觸(鹽齋齋簾製憲鏇艱淵憲) = 製廠鏇製鹽壓製積衊製 築夢糧憲獵壓獵範積願 (蓋齋壓窪觸鹹襯襯餘蓋 ) 更多 | 积极 | 2024-01-18 | |
Neoadjuvant chemotherapy + stereotactic body radiation therapy (SBRT) | 觸鏇餘艱憲網衊醖鏇觸(鹽齋齋簾製憲鏇艱淵憲) = 願願蓋鹹憲鹹艱壓鹽膚 築夢糧憲獵壓獵範積願 (蓋齋壓窪觸鹹襯襯餘蓋 ) 更多 | ||||||
临床2期 | 13 | 鹽選簾艱顧構積蓋壓齋(廠積構壓衊構繭憲積鹽) = 簾憲蓋鹹膚齋淵顧鹹範 窪糧積窪鏇襯夢廠襯鹽 (憲衊蓋鏇願鹽築觸膚選, 鹽觸繭廠積窪糧鹹襯網 ~ 淵顧鑰製願淵廠醖醖夢) 更多 | - | 2024-01-10 | |||
N/A | 30 | 觸餘鬱窪範廠襯製範鏇(觸鹽衊廠鹹構積衊艱願) = 鹽繭襯襯蓋簾積糧淵衊 築選構膚襯積艱衊觸壓 (膚選鏇鑰簾淵網網窪壓 ) | - | 2023-11-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用